BEGIN:VCALENDAR
VERSION:2.0
PRODID:DPCALENDAR
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
X-MICROSOFT-CDO-TZID:13
BEGIN:STANDARD
DTSTART:20251102T090000
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
END:STANDARD
BEGIN:STANDARD
DTSTART:20261101T090000
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20260308T100000
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
END:DAYLIGHT
END:VTIMEZONE
X-WR-TIMEZONE:America/Los_Angeles
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270318
DTEND;VALUE=DATE:20270320
UID:CAD40C48-7A2B-41B6-AE7D-EC27858663E0
SUMMARY:UCLA-UCSF-PCF: PSMA and Beyond Conference 2027
CREATED:20260508T141211Z
DTSTAMP:20260508T141211Z
URL:https://psmaconference.ucsf.edu/
DESCRIPTION:This two-day conference targets radiation oncologists, medical oncologists, nuclear medicine physicians, urologists, radiologists, and advanced practice providers (APPs) involved in managing prostate cancer patients.It will review PSMA PET imaging, including how to interpret and report the imaging and review the current data supporting its use and impacts on patient care. Subsequently, it will focus on PSMA-targeted radioligand therapy to define patient selection and management of treatment. The roles of combination therapy, the impact of future trials, and dosimetry will be presented. Tumor boards will be used to highlight the role of PSMA imaging and therapy in prostate cancer patients. Speakers will include nuclear medicine physicians, medical oncologists, radiation oncologists, urologists, APPs from UCLA and UCSF, and additional thought leaders.Location: San Francisco, CA
X-ALT-DESC;FMTTYPE=text/html:This two-day conference targets radiation oncologists, medical oncologists, nuclear medicine physicians, urologists, radiologists, and advanced practice providers (APPs) involved in managing prostate cancer patients.<br><br>It will review PSMA PET imaging, including how to interpret and report the imaging and review the current data supporting its use and impacts on patient care. Subsequently, it will focus on PSMA-targeted radioligand therapy to define patient selection and management of treatment. The roles of combination therapy, the impact of future trials, and dosimetry will be presented. Tumor boards will be used to highlight the role of PSMA imaging and therapy in prostate cancer patients. Speakers will include nuclear medicine physicians, medical oncologists, radiation oncologists, urologists, APPs from UCLA and UCSF, and additional thought leaders.<br><br>Location: San Francisco, CA
LAST-MODIFIED:20260508T141548Z
SEQUENCE:217
X-ACCESS:1
X-HITS:28
X-COLOR:3366CC
X-SHOW-END-TIME:1
END:VEVENT
END:VCALENDAR